Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Peer Review reports

Original Submission
6 Mar 2022	Submitted	Original manuscript
24 Nov 2022	Reviewed	Reviewer Report
9 Dec 2022	Reviewed	Reviewer Report
15 Mar 2023	Author responded	Author comments - Linde Kehmann
Resubmission - Version 2
15 Mar 2023	Submitted	Manuscript version 2
23 Mar 2023	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
16 May 2023	Editorially accepted
22 May 2023	Article published	10.1186/s12885-023-10972-6

Back to article page